AF-710B

Anavex Life Sciences discussed its fiscal 2024 Q4 results, highlighting the EMA's review of blarcamesine for Alzheimer's treatment, upcoming data presentations, and financials showing a $132.2M cash position with a 4-year runway. The company remains committed to advancing treatments for Alzheimer's and schizophrenia.

Anavex Life Sciences Corp. (AVXL) shares down 30% in 3 months, trading at $5. Developing therapies for neurodegenerative and neurodevelopmental disorders. Lead candidate Anavex 2-73 showed significant cognitive improvement in Alzheimer's phase 2b/3 study. Also in phase II/III for Rett syndrome (EXCELLENCE trial). ANAVEX 3-71 in phase I for Frontotemporal Dementia, Schizophrenia, and Alzheimer's. Cash and equivalents $154.8 million. Stock range $4.90-$15.24 in last year.

Anavex Life Sciences announced preliminary EEG biomarker results from Part A of its Phase 2 study of ANAVEX 3-71 for schizophrenia, showing a dose-dependent effect on key EEG biomarkers with no serious adverse events. Part B, ongoing with more participants and longer treatment, aims for comprehensive efficacy and safety data by H1 2025.